Medication info
Nexium Tablets 20 mg (Esomeprazole Magnesium)

Nexium Tablets 20 mg (Esomeprazole Magnesium)

Prescription medicationTablet
Ingredient · strength
Esomeprazole Magnesium Trihydrate›22.3mg
Manufacturer / importer
AstraZeneca Korea
Appearance
Light pink rectangular film-coated tablet
Packaging
14 tablets (7 tablets/PTP x 2)
Approval status
Active

MFDS item code 200009027 · Approved 2000.10.19 · Insurance code 650700070

Summary

Main use
Treatment of acid-related disorders (including reflux), ulcers (eradication, prevention of rebleeding, etc.), and gastrointestinal disorders caused by anti-inflammatory analgesics
Who uses it
Adults · Children
Adult dosage
1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. · Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer this drug 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning) associated with the use of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Clinical trials extending beyond 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug therapy - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should subsequently be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with a dose of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided and taken twice daily. 6) Maintenance therapy following intravenous treatment to induce prevention of rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous treatment to induce prevention of rebleeding from gastric or duodenal ulcers. 4. Renal impairment: No dose adjustment is necessary. Since there is limited experience administering this drug to patients with severe renal failure, it should be used with caution. 5. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. The dose of this drug should not exceed 20 mg in patients with severe hepatic impairment. 6. Elderly patients: No dose adjustment is necessary.
Children's dosage
2. Adolescents 12 years of age and older - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. 3. Children under 12 years of age: There is no experience administering this drug to children under 12 years of age.

Ingredients

Importer
AstraZeneca Korea

Efficacy & effects

Treatment of acid-related disorders (including reflux), ulcers (eradication, prevention of rebleeding, etc.), and gastrointestinal disorders caused by anti-inflammatory analgesics

  • Gastroesophageal reflux disease
  • erosive reflux esophagitis
  • esophagitis
  • duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
  • rebleeding of gastric ulcers
View approved original text

This medication is used for the treatment of gastroesophageal reflux disease, erosive reflux esophagitis, and maintenance therapy to prevent recurrence in patients with esophagitis. It is also effective for the treatment and prevention of recurrence of duodenal ulcer and peptic ulcer related to Helicobacter pylori infection. It can be applied in the short term for easing upper gastrointestinal pain, discomfort, and burning sensation caused by the intake of non-steroidal anti-inflammatory drugs. It is helpful in the treatment of gastric ulcers caused by prolonged use of non-steroidal anti-inflammatory drugs and is also used for the treatment of Zollinger-Ellison syndrome. Additionally, it is used for maintenance therapy to prevent rebleeding caused by gastric or duodenal ulcers. This medication is used for treating and preventing a variety of gastrointestinal diseases.

Dosage and Administration

Adult dosage

1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. · Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer this drug 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning) associated with the use of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Clinical trials extending beyond 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug therapy - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should subsequently be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with a dose of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided and taken twice daily. 6) Maintenance therapy following intravenous treatment to induce prevention of rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous treatment to induce prevention of rebleeding from gastric or duodenal ulcers. 4. Renal impairment: No dose adjustment is necessary. Since there is limited experience administering this drug to patients with severe renal failure, it should be used with caution. 5. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. The dose of this drug should not exceed 20 mg in patients with severe hepatic impairment. 6. Elderly patients: No dose adjustment is necessary.

Children's dosage

2. Adolescents 12 years of age and older - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. 3. Children under 12 years of age: There is no experience administering this drug to children under 12 years of age.

Precautions

This drug should not be used in patients with specific allergic reactions or hypersensitivity. For example, it should not be administered to patients allergic to this drug, any of its components, or benzimidazole drugs. Care should be taken when administering it in combination with certain antibiotics (penicillin group, macrolide group) used for Helicobacter pylori eradication, especially in patients with hypersensitivity reactions. It may also pose risks when used in combination with certain cardiac medications or antiviral agents, so consultation with healthcare professionals is essential. This medication is not recommended for use by nursing women. Various adverse reactions may occur after administration, including headache, abdominal pain, diarrhea, skin rash, myalgia, and hypomagnesemia. Rarely, severe allergic reactions, liver dysfunction, and severe skin reactions may occur, thus symptoms should be immediately reported to healthcare professionals. Long-term use requires regular testing and monitoring. Caution is advised especially in patients taking it for more than one year as hypomagnesemia and fracture risk may increase. This medication can suppress gastric acid secretion, thereby increasing the risk of bacterial overgrowth in the gastrointestinal tract; if infection symptoms persist, consultation with a physician is necessary. Due to many drug interactions, it is imperative to inform healthcare professionals about currently taken medications, particularly when taking anticoagulants, antiviral agents, certain antibiotics, and antiepileptic drugs. Safety data regarding use during pregnancy is limited, hence it should be used cautiously in pregnant women. There is no specific antidote for dosage overdose, therefore appropriate treatment based on symptoms must be received, and it is important to keep it out of reach of children.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disturbance, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, elevated liver enzymes, jaundice, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal bloating, allergic reaction, back pain, chest pain, sternum pain, facial edema, facial flushing, fatigue, influenza-like illness, generalized edema, leg edema, lethargy, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, thyroid gland enlargement, irritable bowel syndrome, constipation exacerbation, dyspepsia, dysphagia, gastrointestinal malformation, epigastric pain, belching, esophageal disorder, frequent defecation, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorder, pharyngeal disorder, rectal disorder, gastrointestinal symptoms, increased serum gastrin, tongue disorder, tongue edema, ulcerative stomatitis, vomiting, earache, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, nosebleed, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, abnormal liver function, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, arthritis exacerbation, arthropathy, convulsion, fibromyalgia syndrome, hernia, rheumatic polymyalgia, arthralgia, anorexia, apathy, increased appetite, confusion, depression exacerbation, hypertonicity, anxiety, sensory impairment, erectile dysfunction, insomnia, migraine, migraine exacerbation, sleep disorder, tremor, dizziness, visual field defect, paresthesia, drowsiness, dysmenorrhea, menstrual disorder, vaginitis, asthma exacerbation, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, rash, erythematous rash, papular rash, angioedema, dermatitis, itching, urticaria, increased sweating, otitis media, dysosmia, taste loss, taste distortion, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, micturition frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyp or nodule, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric fundic polyp, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, thus it should be stored in a tightly sealed container. Additionally, it is best to store the medication at room temperature that is not excessively hot or cold.

Appearance and packaging

Appearance

Light pink rectangular film-coated tablet

Package unit

14 tablets (7 tablets/PTP x 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.